Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
615 stopped studies mapped to Melanoma and descendants · 90% state a reason
Over the 615 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00087373 | Vaccine Therapy in Treating Patients With Metastatic Melanoma | Phase 2 | terminated | Jul 12, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00671554 | Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant… | Phase 1 / Phase 2 | terminated | May 5, 2008 | Prisma Health-Upstate | Due to business considerations; not due to toxicities or adverse events. | Safety / toxicity |
| NCT01068470 | Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients…(LAK) | — | terminated | Feb 15, 2010 | Loma Linda University | PI left the institution | Investigator |
| NCT00005841 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | Phase 1 | terminated | May 26, 2004 | University of Southern California | Toxicity/Side Effects | Safety / toxicity |
| NCT00006113 | Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or… | Phase 2 | terminated | Jan 27, 2003 | University of Southern California | Lack of efficacy | Efficacy / futility |
| NCT00184067 | Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides… | Phase 2 | terminated | Sep 16, 2005 | University of Southern California | Primary PI left institution | Investigator |
| NCT01166126 | Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV | Phase 2 | terminated | Jul 20, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01689870 | Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma | Phase 1 / Phase 2 | withdrawn | Sep 21, 2012 | Ludwig Institute for Cancer Research | not stated | Not stated |
| NCT00522834 | Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma | Phase 3 | terminated | Aug 30, 2007 | Synta Pharmaceuticals Corp. | not stated | Not stated |
| NCT01055522 | Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With… | Phase 2 | terminated | Jan 25, 2010 | Philogen S.p.A. | not stated | Not stated |
| NCT01933061 | Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus… | Phase 2 | withdrawn | Aug 30, 2013 | Celgene Corporation | Strategic decision not to proceed with the opening of this study. There are no concerns over the… | Safety / toxicity |
| NCT00402662 | A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma | Phase 2 | terminated | Nov 22, 2006 | Yale University | unexpected level of toxicity | Safety / toxicity |
| NCT00278122 | Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That… | Phase 2 | suspended | Jan 18, 2006 | University of Virginia | not stated | Not stated |
| NCT00621439 | Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye | N/A | withdrawn | Feb 22, 2008 | Emory University | no funding- study never began | Funding |
| NCT00358319 | Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma | Phase 1 / Phase 2 | terminated | Jul 31, 2006 | H. Lee Moffitt Cancer Center and Research Institute | PI left Moffitt | Investigator |
| NCT01944709 | Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients… | Phase 1 / Phase 2 | terminated | Sep 18, 2013 | Prof. Dr. Silke Gillessen | Progressive Disease | Other (stated, no rule matched) |
| NCT00147550 | MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma. | Phase 1 / Phase 2 | terminated | Sep 7, 2005 | Pfizer | See termination reason in detailed description. | Other (stated, no rule matched) |
| NCT00965861 | SCRI Tissue Testing Registry | — | terminated | Aug 26, 2009 | SCRI Development Innovations, LLC | Replaced by a study with a similar design. | Other (stated, no rule matched) |
| NCT00722098 | Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat… | Phase 2 | terminated | Jul 25, 2008 | Baylor Research Institute | Early termination due to lesser accrual, and data analysis not done. | Enrollment / accrual |
| NCT00303836 | Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White… | Phase 2 | terminated | Mar 17, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00082875 | Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma | Phase 2 | terminated | May 19, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01216657 | Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma | Phase 2 | terminated | Oct 7, 2010 | Krankenhaus Nordwest | slow recruitment | Enrollment / accrual |
| NCT00357461 | Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated… | Phase 2 | withdrawn | Jul 27, 2006 | Bristol-Myers Squibb | not stated | Not stated |
| NCT00447356 | High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma | Phase 3 | withdrawn | Mar 14, 2007 | Hackensack Meridian Health | There were no patient enrolled in this study at this site | Enrollment / accrual |
| NCT01032122 | Rituximab in Metastatic Melanoma | Phase 1 | terminated | Dec 15, 2009 | Medical University of Vienna | the only reason is that recruitment was not sufficient to meet the planned patient numbers, because… | Enrollment / accrual |
| NCT00087386 | Tanespimycin in Treating Patients With Stage III-IV Melanoma | Phase 2 | terminated | Jul 12, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01340729 | Open-Label Study of TPI 287 for Patients With Metastatic Melanoma | Phase 1 / Phase 2 | withdrawn | Apr 25, 2011 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00937482 | Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases… | Phase 1 | terminated | Jul 13, 2009 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT01416844 | Study of Immune Responses in Patients With Metastatic Melanoma | Phase 2 | withdrawn | Aug 15, 2011 | Providence Health & Services | Change in the development plan for the anti-OX40 antibody. | Other (stated, no rule matched) |
| NCT00003911 | S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited… | Phase 2 | terminated | Apr 12, 2004 | SWOG Cancer Research Network | Poor accrual | Enrollment / accrual |
| NCT01216787 | RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can… | Phase 2 | withdrawn | Oct 7, 2010 | National Cancer Institute (NCI) | Study drug not available. | Other (stated, no rule matched) |
| NCT00006003 | SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated | Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00509496 | Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and… | Phase 2 | terminated | Jul 31, 2007 | National Cancer Institute (NCI) | Low accrual | Enrollment / accrual |
| NCT00085579 | Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or… | Phase 2 | withdrawn | Jun 11, 2004 | Memorial Sloan Kettering Cancer Center | not stated | Not stated |
| NCT00627419 | A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With… | Phase 2 | terminated | Mar 3, 2008 | Infinity Pharmaceuticals, Inc. | Study closed \& recruitment will not recommence | Enrollment / accrual |
| NCT00924001 | Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma | Phase 1 / Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | study was stopped due to low accrual | Enrollment / accrual |
| NCT00492440 | Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or… | Phase 1 | terminated | Jun 27, 2007 | Cytheris SA | not stated | Not stated |
| NCT00512798 | Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or… | Phase 1 / Phase 2 | terminated | Aug 8, 2007 | Vanderbilt-Ingram Cancer Center | This study was terminated due to lack of efficacy | Efficacy / futility |
| NCT01013623 | Stage IV Surgery Versus Best Medical Therapy(STG4SURG) | Phase 3 | terminated | Nov 16, 2009 | Saint John's Cancer Institute | Lack of accrual, lack of continued funding. | Enrollment / accrual |
| NCT00020839 | Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With… | Phase 3 | terminated | Jan 27, 2003 | European Organisation for Research and Treatment of Cancer - EORTC | low accrual | Enrollment / accrual |
| NCT00036816 | Vaccine Therapy in Treating Patients With Melanoma of the Eye | Phase 3 | terminated | Jan 27, 2003 | European Organisation for Research and Treatment of Cancer - EORTC | low accrual | Enrollment / accrual |
| NCT00110123 | Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With… | Phase 3 | terminated | May 4, 2005 | European Organisation for Research and Treatment of Cancer - EORTC | low accrual | Enrollment / accrual |
| NCT00085059 | Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating… | Phase 2 | terminated | Jun 11, 2004 | European Organisation for Research and Treatment of Cancer - EORTC | low accrual | Enrollment / accrual |
| NCT00585000 | A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In… | Phase 1 | terminated | Jan 2, 2008 | AstraZeneca | See termination reason in detailed description. | Other (stated, no rule matched) |
| NCT01026051 | Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT)… | Phase 2 | terminated | Dec 4, 2009 | Mannkind Corporation | Financial/Business Reasons | Funding |
| NCT00369395 | A Study of Volociximab in Metastatic Melanoma | Phase 2 | terminated | Aug 29, 2006 | Abbott | Insufficient clinical activity | Other (stated, no rule matched) |
| NCT00138229 | Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and… | Phase 2 | terminated | Aug 30, 2005 | National Institutes of Health Clinical Center (CC) | not stated | Not stated |
| NCT01003626 | Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma Patients | N/A | withdrawn | Oct 29, 2009 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT01409187 | IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic… | Phase 1 / Phase 2 | withdrawn | Aug 4, 2011 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01106235 | Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating… | Phase 1 | terminated | Apr 19, 2010 | Fred Hutchinson Cancer Center | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 9, 2014source: clinicaltrials